Illumina, Inc. reported second quarter fiscal year 2026 financial results on July 30, 2026, for the period ended June 28, 2026. The company generated $1.16 billion in revenue, representing a 9.5% increase from the prior year and an 8.1% organic growth rate excluding currency, acquisitions, and China impacts. GAAP diluted earnings per share were $1.35, while non-GAAP diluted EPS reached $1.31. Illumina raised its full-year fiscal 2026 revenue guidance to a range of $4.60-$4.64 billion from the previous estimate of $4.52-$4.62 billion and increased non-GAAP diluted EPS guidance to $5.30-$5.40 from $5.15-$5.30. The company operates in the genomics industry, providing DNA sequencing and array-based technologies for research, clinical, and applied markets.

Illumina, Inc. increased its Board of Directors from nine to ten members by appointing Daniel M. Skovronsky, M.D., Ph.D., to the Board, effective immediately. Dr. Skovronsky is an independent director who will stand for election at the 2027 annual meeting of stockholders. Illumina, Inc. is a biotechnology company that provides genomic sequencing technology and sequencing-based information.

Illumina, Inc. announced its financial results for the first quarter ended March 29, 2026, and authorized a new share repurchase program of up to $1.5 billion. This new program is in addition to a previous $1.5 billion authorization that had approximately $314 million in remaining capacity as of April 29, 2026.

Illumina, Inc. announced that directors Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire from the Board effective May 21, 2026. In connection with these departures, the company has nominated David King for election to the Board at the 2026 annual meeting of stockholders.

Illumina, Inc. issued a press release on February 5, 2026, announcing its financial results for the fourth quarter and the full fiscal year ended December 28, 2025. The filing serves as the formal announcement of these results, with the specific financial metrics contained in the accompanying exhibit.